NasdaqCM:BLCM

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. More Details


Snowflake Analysis

Worrying balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has Bellicum Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BLCM has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-2.0%

BLCM

-1.2%

US Biotechs

-1.1%

US Market


1 Year Return

-27.6%

BLCM

30.7%

US Biotechs

15.6%

US Market

Return vs Industry: BLCM underperformed the US Biotechs industry which returned 32.5% over the past year.

Return vs Market: BLCM underperformed the US Market which returned 17.8% over the past year.


Shareholder returns

BLCMIndustryMarket
7 Day-2.0%-1.2%-1.1%
30 Day-2.2%1.3%4.2%
90 Day-8.7%-2.5%6.3%
1 Year-27.6%-27.6%33.0%30.7%18.2%15.6%
3 Year-93.6%-93.6%19.6%13.6%39.6%30.4%
5 Year-95.7%-95.7%8.7%1.0%79.5%59.2%

Price Volatility Vs. Market

How volatile is Bellicum Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Bellicum Pharmaceuticals undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Bellicum Pharmaceuticals is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Bellicum Pharmaceuticals has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Bellicum Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

-18.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BLCM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BLCM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BLCM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BLCM's revenue is expected to decline over the next 3 years (-53.2% per year).

High Growth Revenue: BLCM's revenue is forecast to decline over the next 3 years (-53.2% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BLCM's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Bellicum Pharmaceuticals performed over the past 5 years?

-6.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BLCM is currently unprofitable.

Growing Profit Margin: BLCM is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BLCM is unprofitable, and losses have increased over the past 5 years at a rate of 6.4% per year.

Accelerating Growth: Unable to compare BLCM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BLCM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.1%).


Return on Equity

High ROE: BLCM's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Bellicum Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: BLCM has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: BLCM has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: BLCM has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: BLCM's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BLCM has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: BLCM has less than a year of cash runway if free cash flow continues to reduce at historical rates of 11.3% each year


Next Steps

Dividend

What is Bellicum Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BLCM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BLCM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BLCM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BLCM's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BLCM's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

Rick Fair (51 yo)

3.75yrs

Tenure

US$1,732,888

Compensation

Mr. Richard A. Fair, also known as Rick, serves as Director of Clovis Oncology, Inc since October 11, 2018.served as Chief Executive Officer and President of Bellicum Pharmaceuticals, Inc. since January 31 ...


CEO Compensation Analysis

Compensation vs Market: Rick's total compensation ($USD1.73M) is above average for companies of similar size in the US market ($USD578.04K).

Compensation vs Earnings: Rick's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Richard Fair
President3.75yrsUS$1.73m0.23%
$ 75.2k
Shane Ward
Chief Legal & Strategy Officer and Corporate Secretary2.42yrsUS$606.86k0.027%
$ 8.8k
Alan Smith
Chief Scientific Officer0.33yrUS$791.68k0.014%
$ 4.4k
Atabak Mokari
Chief Financial Officer1.83yrsno datano data
Jaa Roberson
Vice President of Human Resourcesno datano datano data
Aaron Foster
Head of Research & Senior VP1.58yrsno data0.014%
$ 4.6k
David Strauss
Corporate Controller0.75yrno datano data

1.7yrs

Average Tenure

46yo

Average Age

Experienced Management: BLCM's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Richard Fair
President3.75yrsUS$1.73m0.23%
$ 75.2k
Stephen Davis
Independent Director5.25yrsUS$95.51k0%
$ 0
James Brown
Independent Chairman of the Board5.83yrsUS$121.55k0%
$ 0
James Daly
Independent Director4.42yrsUS$74.77k0%
$ 0
Jon Stonehouse
Independent Director5.83yrsUS$99.83k0.020%
$ 6.4k
David Spencer
Member of Scientific & Clinical Advisory Board1.58yrsno datano data
Reid Huber
Independent Director6yrsUS$96.71k0%
$ 0
Daniel Powell
Member of Scientific & Clinical Advisory Board1.58yrsno datano data
Naiyer Rizvi
Member of Scientific & Clinical Advisory Board1.58yrsno datano data
Marco Davila
Member of Scientific & Clinical Advisory Board1.58yrsno datano data
Judith Klimovsky
Independent Director1.83yrsUS$75.55k0%
$ 0
Malcom Brenner
Member of Scientific & Clinical Advisory Board1.58yrsno datano data

2.8yrs

Average Tenure

58yo

Average Age

Experienced Board: BLCM's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.4%.


Top Shareholders

Company Information

Bellicum Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Bellicum Pharmaceuticals, Inc.
  • Ticker: BLCM
  • Exchange: NasdaqCM
  • Founded: 2004
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$32.231m
  • Shares outstanding: 5.06m
  • Website: https://www.bellicum.com

Number of Employees


Location

  • Bellicum Pharmaceuticals, Inc.
  • Life Science Plaza
  • Suite 800
  • Houston
  • Texas
  • 77030
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BLCMNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDDec 2014
BPXADB (Deutsche Boerse AG)YesCommon StockDEEURDec 2014

Biography

Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, an ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/26 23:32
End of Day Share Price2020/10/26 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.